{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:14:47Z","timestamp":1791328487495,"version":"4.3.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"DKFZ Clinician Scientist ProgramCanVirex GmbH"},{"name":"DKFZ Clinician Scientist Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients with cancer frequently receive immune-checkpoint inhibitors (ICIs), which may modulate immune responses to COVID-19 vaccines. Recently, cytokine release syndrome (CRS) was observed in a patient with cancer who received BTN162b2 vaccination under ICI treatment. Here, we analyzed adverse events and serum cytokines in patients with 23 different tumors undergoing (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200964) or not undergoing (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200926) COVID-19 vaccination under ICI therapy in a prospectively planned German single-center cohort study (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009220). We did not observe clinically relevant CRS (\u2265grade 2) after vaccination (95% CI 0\u20135.6%; Common Terminology of Adverse Events v.5.0) in this small cohort. Within 4 weeks after vaccination, serious adverse events occurred in eight patients (12.5% 95% CI 5.6\u201323%): six patients were hospitalized due to events common under cancer therapy including immune related adverse events and two patients died due to conditions present before vaccination. Despite absence of CRS symptoms, a set of pairwise-correlated CRS-associated cytokines, including CXCL8 and interleukin-6 was &gt;1.5-fold upregulated in 40% (95% CI 23.9\u201357.9%) of patients after vaccination. Hence, elevated cytokine levels are common and not sufficient to establish CRS diagnosis.\n                  <\/jats:p>","DOI":"10.1038\/s43018-022-00398-7","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T06:04:51Z","timestamp":1655445891000},"page":"1039-1051","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4835-955X","authenticated-orcid":false,"given":"Thomas","family":"Walle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunanjay","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8567-6020","authenticated-orcid":false,"given":"Joscha A.","family":"Kraske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"R\u00f6sner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane S.","family":"Cussigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina A.","family":"K\u00e4lber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Jasmin","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia Boyoung","family":"Strobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Burghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan M.","family":"Kallenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph K.","family":"Stein-Th\u00f6ringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Jenzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Kahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Hoyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zielske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Skatula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Sawall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias F.","family":"Leber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell Z.","family":"Kunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Krisam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Fremd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Apostolidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Katrin","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg M.","family":"Haag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Zsch\u00e4bitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0344-6027","authenticated-orcid":false,"given":"Niels","family":"Halama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Springfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy","family":"Kirsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"NCT ANTICIPATE Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane S.","family":"Cussigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina A.","family":"K\u00e4lber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Derigs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Dischinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad","family":"Mitri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan A.","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Hohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Woydack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyke","family":"Ferber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Mock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tillmann","family":"Pompecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Schank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Fremd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg M.","family":"Haag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Halama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy","family":"Kirsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Ungerechts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"398_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41416-021-01500-z","volume":"125","author":"B Russell","year":"2021","unstructured":"Russell, B. et al. Risk of COVID-19 death in cancer patients: an analysis from Guy\u2019s Cancer Centre and King\u2019s College Hospital in London. Br. J. Cancer 125, 939\u2013947 (2021).","journal-title":"Br. J. Cancer"},{"key":"398_CR2","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(21)00250-3","volume":"22","author":"D Trapani","year":"2021","unstructured":"Trapani, D. & Curigliano, G. COVID-19 vaccines in patients with cancer. Lancet Oncol. 22, 738\u2013739 (2021).","journal-title":"Lancet Oncol."},{"key":"398_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1158\/2159-8290.CD-20-1817","volume":"11","author":"A Ribas","year":"2021","unstructured":"Ribas, A. et al. Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. Cancer Discov. 11, 233\u2013236 (2021).","journal-title":"Cancer Discov."},{"key":"398_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Karik\u00f3, K. & T\u00fcreci, \u00d6. mRNA-based therapeutics \u2014 developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"398_CR5","doi-asserted-by":"publisher","unstructured":"Frenck, R.W. et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2107456 (2021).","DOI":"10.1056\/NEJMoa2107456"},{"key":"398_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396, 467\u2013478 (2020).","journal-title":"Lancet"},{"key":"398_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2020","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2020).","journal-title":"N. Engl. J. Med."},{"key":"398_CR8","doi-asserted-by":"publisher","unstructured":"Fendler, A. et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat. Cancer https:\/\/doi.org\/10.1038\/s43018-021-00274-w (2021).","DOI":"10.1038\/s43018-021-00274-w"},{"key":"398_CR9","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"398_CR10","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam, A. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Network Open 2, e192535 (2019).","journal-title":"JAMA Network Open"},{"key":"398_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"398_CR12","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum, D. C. & June, C. H. Cytokine storm. N. Engl. J. Med. 383, 2255\u20132273 (2020).","journal-title":"N. Engl. J. Med."},{"key":"398_CR13","doi-asserted-by":"publisher","unstructured":"Au, L. et al. Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01387-6 (2021).","DOI":"10.1038\/s41591-021-01387-6"},{"key":"398_CR14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(21)00155-8","volume":"22","author":"B Waissengrin","year":"2021","unstructured":"Waissengrin, B., Agbarya, A., Safadi, E., Padova, H. & Wolf, I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 22, 581\u2013583 (2021).","journal-title":"Lancet Oncol."},{"key":"398_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","volume":"22","author":"L Monin","year":"2021","unstructured":"Monin, L. et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 22, 765\u2013778 (2021).","journal-title":"Lancet Oncol."},{"key":"398_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2021).","journal-title":"Lancet"},{"key":"398_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jaci.2020.09.018","volume":"147","author":"JM Galv\u00e1n-Rom\u00e1n","year":"2021","unstructured":"Galv\u00e1n-Rom\u00e1n, J. M. et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. J. Allergy Clin. Immunol. 147, 72\u201380.e78 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"398_CR18","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy. Blood 130, 2295\u20132306 (2017).","journal-title":"Blood"},{"key":"398_CR19","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2213-2600(20)30600-7","volume":"9","author":"LYC Chen","year":"2021","unstructured":"Chen, L. Y. C., Hoiland, R. L., Stukas, S., Wellington, C. L. & Sekhon, M. S. Assessing the importance of interleukin-6 in COVID-19. Lancet Resp. Med. 9, e13 (2021).","journal-title":"Lancet Resp. Med."},{"key":"398_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12350-019-01624-z","volume":"26","author":"CJ Morgan","year":"2019","unstructured":"Morgan, C. J. Landmark analysis: a primer. J. Nucl. Cardiol. 26, 391\u2013393 (2019).","journal-title":"J. Nucl. Cardiol."},{"key":"398_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585, 107\u2013112 (2020).","journal-title":"Nature"},{"key":"398_CR22","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586, 594\u2013599 (2020).","journal-title":"Nature"},{"key":"398_CR23","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","volume":"25","author":"F Liang","year":"2017","unstructured":"Liang, F. et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol.Ther. 25, 2635\u20132647 (2017).","journal-title":"Mol.Ther."},{"key":"398_CR24","doi-asserted-by":"publisher","unstructured":"Pelka, K. et al. Spatially organized multicellular immune hubs in human colorectal cancer. Cell https:\/\/doi.org\/10.1016\/j.cell.2021.08.003 (2021).","DOI":"10.1016\/j.cell.2021.08.003"},{"key":"398_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002261","volume":"9","author":"DV Maslov","year":"2021","unstructured":"Maslov, D. V. et al. Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer. J. Immunother. Cancer 9, e002261 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"398_CR26","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","volume":"27","author":"JB Iorgulescu","year":"2021","unstructured":"Iorgulescu, J. B. et al. Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma. Clin. Cancer Res. 27, 276\u2013287 (2021).","journal-title":"Clin. Cancer Res."},{"key":"398_CR27","doi-asserted-by":"publisher","first-page":"1886725","DOI":"10.1080\/2162402X.2021.1886725","volume":"10","author":"A Valachis","year":"2021","unstructured":"Valachis, A. et al. Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors. OncoImmunology 10, 1886725 (2021).","journal-title":"OncoImmunology"},{"key":"398_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11782-w","volume":"10","author":"Z Sun","year":"2019","unstructured":"Sun, Z. et al. A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nat. Commun. 10, 3874 (2019).","journal-title":"Nat. Commun."},{"key":"398_CR29","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","volume":"385","author":"D Mevorach","year":"2021","unstructured":"Mevorach, D. et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N. Engl. J. Med. 385, 2140\u20132149 (2021).","journal-title":"N. Engl. J. Med."},{"key":"398_CR30","doi-asserted-by":"publisher","first-page":"e024537","DOI":"10.1136\/bmjopen-2018-024537","volume":"9","author":"R Phillips","year":"2019","unstructured":"Phillips, R., Hazell, L., Sauzet, O. & Cornelius, V. Analysis and reporting of adverse events in randomised controlled trials: a review. BMJ Open 9, e024537 (2019).","journal-title":"BMJ Open"},{"key":"398_CR31","doi-asserted-by":"publisher","unstructured":"Strobel, S.B., Machiraju, D., K\u00e4lber, K.A. & Hassel, J.C. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment. Cancer Immunol. Immunother. https:\/\/doi.org\/10.1007\/s00262-021-03133-w (2021).","DOI":"10.1007\/s00262-021-03133-w"},{"key":"398_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/cncy.20147","volume":"119","author":"HM Moore","year":"2011","unstructured":"Moore, H. M. et al. Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol. 119, 92\u2013102 (2011).","journal-title":"Cancer Cytopathol."},{"key":"398_CR33","doi-asserted-by":"crossref","unstructured":"Miroglio, B., Zeber, D., Kaye, J. & Weiss, R. The effect of ad blocking on user engagement with the web. In: Proc. 2018 World Wide Web Conference 813\u2013821 (International World Wide Web Conferences Steering Committee, Lyon, France, 2018).","DOI":"10.1145\/3178876.3186162"},{"key":"398_CR34","unstructured":"Walle, T. Wallet-maker\/ANTICIPATE_COVID-19. Zenodo https:\/\/zenodo.org\/record\/6544522#.YoYUQXXMLcs (2022)."}],"updated-by":[{"DOI":"10.1038\/s43018-022-00420-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000}}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-022-00398-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-022-00398-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-022-00398-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T05:01:52Z","timestamp":1669352512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-022-00398-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["398"],"URL":"https:\/\/doi.org\/10.1038\/s43018-022-00398-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.08.21267430","asserted-by":"object"}]},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"24 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s43018-022-00420-y","URL":"https:\/\/doi.org\/10.1038\/s43018-022-00420-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.W. reports previous and current stock ownership of various pharmaceutical companies manufacturing SARS-CoV-2 vaccines and diagnostics including BionTech, Astra Zeneca and Roche. T.W. also reports research support from CanVirex, a spin-off company of the Heidelberg University Hospital developing viral vector-based immunotherapies and vaccines (financial support for blood sampling materials). G.U. is founder and current CMO\/CSO of CanVirex, Basel, Switzerland. G.M.H. reports consulting or advisory roles (unrelated) at Bristol-Myers Squibb, MSD Sharp & Dohme, Lilly, Novartis and Daiichi Sankyo; honoraria (unrelated) from Servier, MSD Sharp & Dohme, Lilly, Targos, Bristol-Myers Squibb, IOMEDICO and MCI Conventions; research funding (unrelated) from Nordic Pharma, Taiho Pharmaceutical, MSD Sharp & Dohme, Janssen, Astra Zeneca and IKF Klinische Krebsforschung Frankfurt; and travel\/accommodations (unrelated) from Bristol-Myers Squibb, Lilly, Servier and MSD Sharp & Dohme. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}